Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis

被引：0
|
作者：
De Mello, Ramon Andrade [1 ]
Aguiar, Pedro, Jr. [2 ]
Cabral, Paloma [3 ]
Chaves, Fablo [4 ]
Liu, Davi [2 ]
Soares, Joao Paulo [4 ]
Mountzios, Giannis [5 ]
Tadokoro, Hakaru [2 ]
Lopes, Gilberto De Lima [6 ]
机构：
[1] Univ Algarve, Biomed Sci & Med Oncol Div, Faro, Portugal
[2] Univ Fed Sao Paulo, Med Oncol, Sao Paulo, Brazil
[3] Univ Fed Ceara, Med, Fortaleza, Ceara, Brazil
[4] Inst Canc Ceara, Med Oncol, Fortaleza, Ceara, Brazil
[5] Univ Athens, Sch Med, Med Oncol, Athens, Greece
[6] Ctr Paulista Oncol E Hcor Onco, Oncoclin Brasil Grp, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
gefitinib; Erolotinib; afatinib; Non-small-cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-081
引用
收藏
页码：S1239 / S1240
页数：3
相关论文
共 50 条
  • [1] Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
    Qi, Wei-Xiang
    Sun, Yuan-Jue
    Shen, Zan
    Yao, Yang
    JOURNAL OF CHEMOTHERAPY, 2015, 27 (01) : 40 - 51
  • [2] Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis
    Yu, Guo-Can
    Yang, Jun
    Ye, Bo
    Xu, Li-Liang
    Li, Xiao-Yuan
    Zheng, Guan-Rong
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2019, 16 (06) : 7659 - 7670
  • [3] A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
    Chen, Shuo
    Hu, Bin
    Li, Hui
    ONCOTARGETS AND THERAPY, 2018, 11 : 7691 - 7697
  • [4] Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis
    Zhang, Yaxiong
    Sheng, Jin
    Yang, Yunpeng
    Fang, Wenfeng
    Kang, Shiyang
    He, Yang
    Hong, Shaodong
    Zhan, Jianhua
    Zhao, Yuanyuan
    Xue, Cong
    Ma, Yuxiang
    Zhou, Ting
    Ma, Shuxiang
    Gao, Fangfang
    Qin, Tao
    Hu, Zhihuang
    Tian, Ying
    Hou, Xue
    Huang, Yan
    Zhou, Ningning
    Zhao, Hongyun
    Zhang, Li
    ONCOTARGET, 2016, 7 (15) : 20093 - 20108
  • [5] Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer
    Franek, Jacob
    Cappelleri, Joseph C.
    Larkin-Kaiser, Kelly A.
    Wilner, Keith D.
    Sandin, Rickard
    FUTURE ONCOLOGY, 2019, 15 (24) : 2857 - 2871
  • [6] An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
    Qi, Yuexiao
    Xia, Xiaojun
    Shao, Lihua
    Guo, Liyun
    Dong, Yumei
    Tian, Jinhui
    Xu, Lijun
    Niu, Ruijun
    Wei, Shihong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
    T. T. Zhang
    R. M. Wang
    Z. Yang
    G. B. Chen
    Clinical and Translational Oncology, 2016, 18 : 576 - 581
  • [8] Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
    Zhang, T. T.
    Wang, R. M.
    Yang, Z.
    Chen, G. B.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06) : 576 - 581
  • [9] Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
    Wang, Yingtian
    Wang, Mingzhen
    Wang, Qiaoxia
    Geng, Zhiying
    Sun, Mingxiang
    ONCOTARGET, 2017, 8 (17) : 29406 - 29415
  • [10] Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
    Pan, Jie
    Cai, Xiaoping
    Cao, Zhuo
    Pan, Jiongwei
    Zheng, Hao
    PHARMACOLOGY, 2023, 108 (01) : 8 - 16
12345